Future Journal of Pharmaceutical Sciences

Table 6 Results of robustness of 100% level solution

From: An effective stability indicating RP-HPLC method for simultaneous estimation of Dolutegravir and Lamivudine in bulk and their tablet dosage form

Variation of parameter		Lamivudine					Dolutegravir
Variation of parameter		RT	Peak area	USP plate count	USP tailing factor	% assay	RT	Peak area	USP plate count	USP tailing factor	% assay
Mobile phase ratio (± 1 ml)	14:86	3.349	10,691,540	7172	1.06	99.92	5.068	4,144,878	9943	1.06	100.3
	15:85	3.34	10,699,768	7146	1.05	100	5.065	4,131,557	9923	1.05	100
	16:84	3.348	10,713,746	7120	1.06	100.1	5.068	4,155,623	10,022	1.06	100.9
Flow rate (± 0.1 ml)	0.7 ml	3.817	10,734,389	7252	1.7	100.3	5.786	4,912,661	10,671	1.06	107.5
	0.8 ml	3.34	10,699,768	7146	1.05	100	5.065	4,131,307	9923	1.05	100
	0.9 ml	2.983	9,614,165	6696	1.7	89.85	4.51	3,708,003	9617	1.05	96.91
Maximum wavelength (± 2 nm)	256	3.347	10,699,769	7321	1.06	100	5.065	4,131,307	9984	1.06	100.6
	258	3.34	10,699,768	7146	1.05	100	5.065	4,131,307	9923	1.05	100
	260	3.349	10,691,540	7296	10.5	99.92	5.068	4,144,851	9636	1.061	97.1

RT retention time; slight change in method parameter could not affect the USP plate count and taliling factor

Back to article page